The medical system is Expanding Their weight loss program is as an estimate place One billion adults and children worldwide are affected by obesity.
Although the World Health Organization Said Weight loss drugs are not the only solution to rising obesity rates, and the GLP-1 industry, such as Ozempic, continues to boom.
Here are eight updates on type 2 diabetes drugs and the market.
1. Viking Therapeutics, a San Diego-based pharmaceutical company; report The drug candidate VK2735 achieved positive results in a Phase 2 trial. The treatment is a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, similar to Eli Lilly's weight loss drug Zepbound (tirzepatide).
In this study, patients lost 14.7% of their body weight. This is a more promising result than Eli Lilly's tirzepatide or Novoher Nordisk's semaglutide (Ozempic, Wegovy).
2. The FDA may expand the label for Wegovy, Novo Nordisk's approved weight loss drug, which contains the same active ingredient as Ozempic. In mid-February, FDA Commissioner Robert Califf indicated that a cardiovascular disease indication could be included on Wegovy's label in 2024. end point report.
In the Phase 3 trial, Novo Nordisk found Wegovy reduced heart failure-related symptoms and helped patients avoid 20% of serious cardiovascular events.
3. Yes no agreement yet As to whether or when patients are able to maintain weight loss after stopping GLP-1. However, the injections cost about $1,000 for a four-week supply, leading some patients to rely on older drugs or switch to other GLP-1s.
a study lancet A paper published on February 19 found that unhealthy weight gain may be the culprit. stopped Along with exercise. Of about 100 obese patients, those who exercised while taking weight-loss drugs retained more muscle and kept much more weight off the drugs than those who did not exercise. Ta.
4. Bariatric surgery is recommended in clinical trials between four health systems. even more effective It is more effective than medical or lifestyle interventions for people with diabetes. The study tracked the outcomes of 262 patients who underwent bariatric surgery or medical/lifestyle management between 2007 and 2013.
5. The doctor look With GLP-1, an increasing number of patients are seeking plastic surgery to remove sagging and excess skin.Unintended consequences used to be dubbed “Ozempik face” refers to a face that becomes shriveled due to rapid weight loss.
6. Grocery expenses Diminished Data from more than 90,000 U.S. households shows between 6% and 9% of households with GLP-1 users. Once GLP-1 was discontinued, monthly grocery spending returned to previous levels.
7. Approximately 4,000 prescriptions for adolescents were issued in 2023. written Wegovy and Ozempic weight loss purpose – rapid growth compared to a few years ago.
According to the CDC, nearly 20% of children are obese, and obesity often leads to other diseases such as type 2 diabetes, high blood pressure, asthma, and joint problems.
8. Over the next four years or so, GLP-1 will Be expected Analysts at Goldman Sachs say it will boost the U.S. economy by $1 trillion. By 2030, the anti-obesity drug market could reach $100 billion, which is 16 times its current value.
Ripple effects are being felt in industries beyond pharmaceuticals, with junk food companies pivoting their strategies to reduce the calorie intake of Walmart shoppers.
The market is already transforming the Danish economy, where Novo Nordisk is headquartered. In late February, the country became Europe's third most prosperous economy, despite being the continent's 22nd most populous country.
